If you would like more information about the profile please click
. You will be directed to a new page where you will need
to provide some information about yourself/your business cooperation needs and submit
your expression of interest in the profile . A Network Partner will then contact
you to discuss your interest in greater detail.
A German research institution has generated positive data on the use of interleukin-22 binding protein as biomarker for prediction and monitoring of the individual efficacy of anti-TNF-alpha treatments of Inflammatory Bowel Disease and other chronic inflammatory conditions. Sought are SMEs and MNEs of any size, which are involved in the development of such treatments, especially for optimization of anti-TNF-alpha therapy for licensing, transfer of rights, knowledge transfer, or R&D cooperation.
The pathogenesis of Inflammatory Bowel Disease (IBD) remains still unclear, yet it has been closely related to the inflammatory response. Current therapies target tumor necrosis factor alpha (TNF-alpha) to inhibit its inflammatory effects. The success of the therapy is monitored through observation of clinical symptoms and TNF-alpha antibodies level. This yields a limited amount of information, since the effects of the treatment are only detectable with the development of the patient’s wellbeing, hence in only ~ 50 % of the cases TNF-alpha-based treatments of IBD have the expected therapeutic effect. This inefficient monitoring entails remarkable disadvantages for the patient and health system, due to the side effects and high costs associated to TNF-alpha-blockers treatment.
A German research group has generated positive data on the novel use of interleukin-22 binding protein (IL-22BP) as biomarker for the prediction and monitoring of the efficacy of anti-TNF-alpha treatments, allowing its consistent use. IL-22BP regulates the function of the free interleukin, and its downregulation apparently has a positive effect on the therapy. Therefore, monitoring IL-22BP could be used to predict therapy effectiveness and for measuring the course of the disease in treated patients. This would allow an early adaption or optimization of therapy conditions to the patient in a usually lifelong treatment thereby reducing costs and increasing wellbeing. The positive results generated so far are being currently validated in the frame of a prospective study.
Partners could be enterprises of any size, both SMEs or MNEs, which are preferably active in the fields of Inflammatory Bowel Disease treatment, optimization of anti-TNF-alpha therapy, and personalized medicine. They could benefit from a transfer of rights of the existing IP (patent pending), licensing, knowledge transfer, or R&D collaborations to test and refine the technology in commercially relevant projects. In focus of a possible collaboration could be the development of a market-ready diagnostic assay, or the support of prospective studies with larger groups of patients.
Reduced treatment time
Reduced treatment costs
Minimization of related side effects
Personalization to patient
Tests in patient cohort ongoing
PCT application pending
Sought are industrial partners of any size, both SMEs or MNEs, which are preferably involved in the treatment of Inflammatory Bowel Disease, optimization of anti-TNF-alpha therapy, and personalized medicine in general.
Partners are sought for licensing, transfer of rights (pending patent), knowledge transfer, or R&D collaborations to test and refine the technology in commercially relevant projects. In focus of a possible collaboration could be the development of a market-ready diagnostic assay, or the support of prospective studies with larger groups of patients.